58m
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After First U.S. BiPASS Phase 3 Patient Dosed
Telix Pharmaceuticals (ASX:TLX) has just dosed the first U.S. patient in its BiPASS Phase 3 trial, drawing fresh attention to how Illuccix and Gozellix might shape prostate cancer diagnosis and future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback